Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast
Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
General14 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News24 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General14 hours agoOf saints and sinners | The Spectator Australia
-
Noosa News19 hours agoBrisbane rising on global rankings, but still behind southern capitals